Nuvectra Corporation (NVTR) Receives Daily Media Impact Rating of 0.21
News stories about Nuvectra Corporation (NASDAQ:NVTR) have been trending somewhat positive recently, Accern Sentiment reports. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Nuvectra Corporation earned a coverage optimism score of 0.21 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.669854603509 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Several analysts have commented on NVTR shares. Zacks Investment Research upgraded shares of Nuvectra Corporation from a “sell” rating to a “hold” rating in a report on Tuesday, May 30th. ValuEngine upgraded shares of Nuvectra Corporation from a “sell” rating to a “hold” rating in a report on Friday, June 16th. TheStreet upgraded shares of Nuvectra Corporation from a “d” rating to a “c-” rating in a report on Monday, June 19th. Finally, Piper Jaffray Companies restated a “neutral” rating and issued a $14.00 price objective on shares of Nuvectra Corporation in a report on Thursday, July 6th. Three analysts have rated the stock with a hold rating and one has given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $10.50.
Shares of Nuvectra Corporation (NASDAQ NVTR) traded up 4.21% during mid-day trading on Wednesday, reaching $11.39. 30,171 shares of the company’s stock traded hands. Nuvectra Corporation has a 12-month low of $4.63 and a 12-month high of $11.39. The firm’s market capitalization is $121.86 million. The stock has a 50-day moving average price of $10.61 and a 200 day moving average price of $7.98.
Nuvectra Corporation (NASDAQ:NVTR) last released its quarterly earnings data on Tuesday, August 8th. The company reported ($1.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.14) by $0.07. The company had revenue of $7.20 million during the quarter, compared to analysts’ expectations of $5.96 million. Nuvectra Corporation had a negative net margin of 232.31% and a negative return on equity of 56.68%. The firm’s quarterly revenue was up 188.0% on a year-over-year basis. During the same period in the previous year, the company earned ($0.85) EPS. Analysts anticipate that Nuvectra Corporation will post ($4.77) EPS for the current fiscal year.
In related news, CEO Scott F. Drees acquired 10,000 shares of the stock in a transaction on Friday, August 11th. The stock was bought at an average cost of $11.72 per share, with a total value of $117,200.00. Following the transaction, the chief executive officer now directly owns 125,180 shares in the company, valued at $1,467,109.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 3.60% of the stock is owned by insiders.
Nuvectra Corporation Company Profile
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs.
Receive News & Ratings for Nuvectra Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra Corporation and related companies with MarketBeat.com's FREE daily email newsletter.